Jove
Visualize
Contact Us

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. The Reconcile Study Protocol: Exploiting Image-based Risk Stratification In Early Prostate Cancer To Discriminate Progressors From Non-progressors (reconcile).
  1. Home
  3. The Reconcile Study Protocol: Exploiting Image-based Risk Stratification In Early Prostate Cancer To Discriminate Progressors From Non-progressors (reconcile).

Related Experiment Video

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.4K

The RECONCILE study protocol: Exploiting image-based risk stratification in early prostate cancer to discriminate

Teresa Marsden1,2, Gerhardt Attard3, Shonit Punwani4

  • 1UCL Division of Surgical & Interventional Science, University College London, London, United Kingdom.

Plos One
|October 17, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

More Related Videos

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
08:40

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging

Published on: April 8, 2016

12.8K
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

141

Related Experiment Videos

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy
09:11

Use of MRI-ultrasound Fusion to Achieve Targeted Prostate Biopsy

Published on: April 9, 2019

21.4K
Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging
08:40

Quantitation of Protein Expression and Co-localization Using Multiplexed Immuno-histochemical Staining and Multispectral Imaging

Published on: April 8, 2016

12.8K
A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound
06:08

A Cognitive Fusion-guided Prostate Biopsy Using Multiparametric Magnetic Resonance Imaging and Transrectal Ultrasound

Published on: March 21, 2025

141

The RECONCILE study investigates molecular and radiomic markers for prostate cancer progression in Gleason 3+4 tumors. Ongoing recruitment aims to link molecular changes with radiological progression for better treatment strategies.

Area of Science:

  • Oncology
  • Radiology
  • Genomics

Background:

  • The RECONCILE study (NCT04340245) focuses on localized, newly diagnosed Gleason 3+4 prostate tumors.
  • It aims to identify molecular and radiomic markers linked to clinical and radiological progression.

Purpose of the Study:

  • To identify molecular and radiomic markers associated with clinical and radiological progression in intermediate-risk prostate cancer.
  • To correlate molecular markers with standard MRI-targeted histology and oncological outcomes.

Main Methods:

  • A prospective, longitudinal, observational cohort study of 60 treatment-naïve participants with Gleason 3+4 prostate cancer.
  • Collection of blood, urine, and prostate tissue for next-generation sequencing at baseline and one year.
  • Radiomic analysis of standard-of-care MRI data to assess radiological progression (PRECISE score 4 or 5).

Main Results:

  • Recruitment commenced in July 2020, enrolling 62 participants.
  • Tissue analysis is underway, with 37 participants having donated samples to date.

Conclusions:

  • A prospective study has been established to evaluate the molecular landscape of intermediate-risk, MRI-visible prostate tumors.
  • The study is ongoing, with recruitment continuing to gather comprehensive data.